40 results about "Amino acid supplementation" patented technology

The present invention is directed to modified antibodies, including anti-TNFα antibodies, in which C-terminal amino acids of heavy chain sequences are modified from a native sequence of proline-glycine-lysine (“PGK”) to one that includes a proline positioned between the glycine and lysine, resulting in a C-terminal sequence of proline-glycine-proline-lycine (“PGPK”). The invention further provides methods of producing and using such antibodies.

The invention discloses a preparation method of polypeptide solid-phase synthesis bivalirudin crude product. The preparation method comprises the following steps of: (1) mixing Fmoc-amino-acid resin or Fmoc-polypeptide resin and an unprotecting agent and removing Fmoc protecting group; (2) in the existence of a condensing agent, leading amino acid with Fmoc or Boc and amino acid or polypeptide onthe resin to carry out condensation; (3) repeating the step (1) and step (2) and obtaining polypeptide resin shown as formula II; and (4) in the existence of a cutting agent, leading the polypeptide and the resin on the polypeptide resin to be separated, and obtaining bivalirudin shown as formula I. The unprotecting agent contains 3 to 20 percent of piperidine and 0.5 to 10 percent of bicyclic amidine by total volume.

The present invention encompasses an amino acid composition for recovery of muscle strength and function.

The invention aims to provide an active polypeptide separated from an anchovy fermentation liquid. The molecular weight of the nerve cell injury resistant polypeptide obtained by the invention is 2,181Da; and the polypeptide is composed of 11 amino acids such as aspartic acid, threonine, glutamic acid, glycine, alanine, isoleucine, tyrosine, phenylalanine, histidine, lysine, arginine and the like, and is a novel active polypeptide with activity. According to the polypeptide obtained by the invention, in a glutamine nerve cell injury model, the addition of the active polypeptide provided by the invention can obviously increase the survival rate of PC12 nerve cells; and when the final concentration is 50 mug / mL, the cell survival rate is increased by 26.4% in comparison with an injury group, thereby effectively relieving glutamine-induced nerve cell injury. Besides, the cell mechanism study on the nerve cell protective action of the polypeptide discovers that the addition of the active polypeptide obviously increases the intracellular total oxidation resistance and has a certain promoting action on increase of SOD (superoxide dismutase) activity.

The present invention discloses glutamate dehydrogenase mutants and an application thereof. The glutamate dehydrogenase mutants are one of the following: mutating 402th lysine of an amino acid sequence shown in SEQ ID NO.1 to phenylalanine or aspartic acid; mutating 406th isoleucine to phenylalanine or threonine; conducting combined mutation of 121th threonine and 123th leucine; and conducting combined mutation of 379th alanine and 383th leucine. A molecular transformation method combining directed evolution with semi-rational design significantly improves catalytic activity of glutamate dehydrogenase derived from pseudomonas putida to 2-carbonyl-4-(hydroxymethylphosphono)butyric acid (PPO) and solves a problem of low glutamate dehydrogenase activity in preparation of L-glufosinate by a reductive amination method.

A feed supplement for increasing the plasma amino acid level of animals, including animal feed and liquid lysine base, where the liquid lysine base has a concentration between about 45% and about 55%, and has a pH level of between about 9.5 and about 10.5, a chloride content between about 0.10% and about 0.15%, a bulk density of between about 1.14 and about 1.17 g / cm3, and a maximum moisture level of between about 42% and about 48%. The animal feed may either be dry feed, liquid feed, drinking water or milk replacers, or a combination thereof. The present invention also includes a method of increasing the plasma amino acid level of animals, including the steps of providing animal feed, and supplementing the animal feed with an amino acid supplement comprising liquid lysine base having a concentration between about 45% and about 55%, and having a pH level of between about 9.5 and about 10.5.

The invention relates to health-caring blend oil rich in alpha-linolenic acid and nervonic acid, as well as a detection method thereof. The health-caring blend oil rich in the alpha-linolenic acid and the nervonic acid comprises the following ingredients in parts by weight: 10-45 parts of linseed oil, 0-15 parts of deep-sea shark oil, 0-10 parts of sorbifolia oil, 5-45 parts of walnut oil, 0-15 parts of tomato seed oil, 0-35 parts of camellia oleifera seed oil, 0-15 parts of olive oil, 3-25 parts of perilla seed oil, and 1-8 parts of black sesame seed oil; and the characteristic fatty acid compositions and the contents thereof are detected by combining HS-SPME-GC-MS. The linseed oil, the deep-sea shark oil, the sorbifolia oil, the camellia oleifera seed oil, the walnut oil, the olive oil, the tomato seed oil, the perilla seed oil and the black sesame seed oil are combined in the blend oil so as to prepare the health-caring blend oil; the ingredients are rationally matched, and health-caring blend oil of different types can be blended according to dietary structures of different populations. The prepared health-caring blend oil is capable of supplementing amino acid, vitamins, minerals and trace elements needed by the human body, as well as keeping nutrition balance; moreover, the blended final products are good in taste, color and luster, and are capable of increasing appetite.

The invention relates to a high concentration glycerol-type minoxidil tincture for treating alopecia and a preparation method thereof. The high concentration glycerol-type minoxidil tincture of the invention comprises components of minoxidil, alcohol, glycerol, water-soluble azone, acids, ethylene diamine tetraacetic acid, arginine, cystine and water. Traditional propylene glycol is substituted by glycerol and water-soluble azone, so as to realize a minoxidil concentration of 5-15%, solve allergic problem caused by propylene glycol and realize a high minoxidil dissolving concentration; amino acids are added in the components to increase hair growing speed; when necessary, the arginine and / or sodium hydroxide is added with a pH buffer solution to stabilize a scalp pH at an optimum pH andavoid discomfort and hair shedding caused by pH change along with application of the hair grower. The invention employs a minoxidil step-by-step dissolving method with a short dissolving time to solve a problem of minoxidil oxidation during dissolving in a traditional technology.

A method of improving health in an animal includes administering to the animal a nutritional supplement comprising an amino acid secretagogue composition, which stimulates the pituitary gland in the animal to produce growth hormone. The nutritional supplement may be administered orally. The nutritional supplement may comprise L-arginine hydrochloride, L-pyroglutamic acid, L-lysine hydrochloride, and cysteine. When desired, the nutritional supplement may consist essentially of L-arginine hydrochloride, L-pyroglutamic acid, L-lysine hydrochloride, N-acetyl-L-cysteine, L-glutamine, and schizonepeta powder.

The present invention pertains to a nutritional composition for reconstituting an optimal healthy microbiota ecosystem in humans or animals. In particular, the present invention relates to an ingestible carrier containing specific amino acids designed to favor the growth of bacteria favorable to individuals health or for reducing the risk of developing deleterious events. The invention also pertains to the use of specific amino acids for reconstituting an optimal healthy microbiota ecosystem in humans or animals, in particular in infants, critically ill patients, in the case of chronic diseases or any stresses impacting the gut and in elderly people.

The invention relates to a cancer antigen 125 (CA125) enzyme-linked immune adsorption detection kit, which can directly detect the concentration of the CA125 in human serum rapidly. The kit has the main technical characteristics that a monoclonal antibody is prepared by selecting a specific amino acid sequence in a CA125 exon 1; a rabbit-anti CA125 polyclonal antibody is prepared by selecting a specific amino acid sequence in a CA125 exon 3. When the detection is performed, samples can be combined with the solid-phase monoclonal antibody and the enzyme labeled rabbit-anti CA125 polyclonal antibody. The increase of CA125 level in the serum often occurs in case of ovarian cancer, endometritis and other cancers. The detection kit can be used for detecting ovarian cancer, etc. and assessing the treatment prognosis effect.

The invention discloses an enteral nutrition preparation containing marine bioactive polysaccharides. The preparation is prepared from ingredients of milk, marine bioactive polysaccharides, marine bioprotein powder, composite fruit and vegetable juice and the like. The invention also discloses a preparation method of the enteral nutrition preparation containing marine bioactive polysaccharides. The method comprises the steps of preparing the marine bioactive polysaccharides; preparing marine bioprotein powder; preparing the composite fruit and vegetable juice; performing stirring, homogenizingand the like. The marine bioactive polysaccharide ingredient of the enteral nutrition preparation containing marine bioactive polysaccharides has the effects of resisting tumor, resisting virus, resisting cardiovascular diseases, resisting oxidization, regulating immunity and the like; the resistance capability of the body can be obviously enhanced; the occurrence of complications such as postoperative infection can be reduced. The marine bioprotein powder of the enteral nutrition preparation contains rich protein; the enteral nutrition preparation is used as amino acid supplementation food;the composite fruit and vegetable juice is added into the enteral nutrition preparation, so that the nutrition preparation has the typical fruit and vegetable fragrance and nutrition ingredients.

The present invention relates to anti-human respiratory syncytial virus N protein antibodies and immunochromatographic kit for detection of human respiratory syncytial virus by using the same. The anti-human respiratory syncytial virus N protein antibodies separately recognize two linear epitopes consisting of No.21-34 amino acids and No.226-239 of human respiratory syncytial virus N protein; the human respiratory syncytial virus N protein has sequence number of AAB59852.1 in GenBank; amino acid sequence of sites No.21-34 and No.226-239 of the human respiratory syncytial virus N protein are respectively SKYTIQRSTGDSID and FGIAQSSTRGGSRV. The two kinds of rabbit anti-human respiratory syncytial virus N protein antibodies have the characteristics of good specificity, high purity, high titer and low preparation cost.

The invention discloses application of a procoagulant polypeptide LGTX-F2 to preparation of coagulation drugs. The procoagulant polypeptide LGTX-F2 contains 65 amino acid residues, wherein the molecular weight of the procoagulant polypeptide LGTX-F2 is 7444.51 Da, the isoelectric point is 7.75 and the amino acid sequence of the procoagulant polypeptide LGTX-F2 is as shown in a SEQ ID: 1. The procoagulant polypeptide LGTX-F2 disclosed by the invention is expressed by escherichia coli, has very remarkable coagulant activity and can be applied to preparation of the coagulation drugs.

The present invention discloses a glutamate oxidase mutant, a nucleic acid molecule, applications of the glutamate oxidase mutant, and a method for preparing ketoglutaric acid, wherein the amino acidsequence of the glutamate oxidase mutant is represented by SEQ ID NO.1. According to the present invention, the glutamate oxidase mutant can catalyze the formation of ketoglutaric acid from glutamic acid, and has high catalytic ability compared with the wild type glutamate oxidase.

The invention discloses a mutant of an endotoxin neutralizing peptide, which is prepared by substituting at least two of the fifth, eighth, eleventh and fifteenth amino acid residues of the endotoxin neutralizing peptide consisting of the amino acid sequence represented by SEQ ID No. 1 with the following corresponding amino acid residues: alanine which substitutes lysine, namely the fifth amino acid residue; tryptophan which substitutes phenylalanine, namely the eighth amino acid residue; lysine which substitutes glutamine, namely the eleventh amino acid residue; and lysine which substitutes aspartic acid, namely the fifteenth amino acid residue. The mutant of the endotoxin neutralizing peptide of the invention can inhibit the combination of LBP and LPS by directly neutralizing competitiveness and activity of the LPS, inhibit an LPS induced excessive inflammatory response in vitro and in vivo, has a stronger function than aparental endotoxin-neutralizing peptide from the LBP, has no visible cytotoxicity and can be applied in the preparation of medicaments for preventing and treating endotoxin associated inflammations caused by Gram-negative bacterium infection.

The present invention is related to a pharmaceutical composition for a liver-receptor imaging injection, the pharmaceutical composition including a bi-functional compound which has a ASGPR specificity, wherein the bi-functional compound includes a backbone of alpha-amino acid (or the derivatives thereof) and a poly-galactosamine chain (or a poly-lactose chain) connected to the alpha-amino acid. Thereby, the pharmaceutical composition can quantify potential of liver storage ability and evaluate severity of the course of liver disease. A liver-receptor imaging injection using the same and the one-step dispensing method thereof are also provided to improve defects of iodine-labeled and overcome disadvantages of the reduced labeling-yield and the instability after autoclave sterilization.

The invention relates to an L-glutamate oxidase gene from Streptomyces griseoflavus as well as a preparation method and application of the L-glutamate oxidase gene. The nucleotide sequence of the L-glutamate oxidase gene is represented by SEQ ID No.1, the total length is 2004bp, and the amino acid sequence of an encoded protein of the L-glutamate oxidase gene is represented by SEQ ID No.2. A Streptomyces griseoflavus stain for producing L-glutamate oxidase is screened from soil, a full-length sequence of the L-glutamate oxidase gene is obtained from the strain, the L-glutamate oxidase gene with the nucleotide sequence represented by SEQ ID No.1 is obtained, and the L-glutamate oxidase gene is synthesized by virtue of a gene synthetic method, so that the cost for extracting L-glutamate oxidase from wild fungi is greatly lowered, and the catalytic activity of L-glutamate oxidase is increased; and meanwhile, a L-glutamate oxidase substrate has very strong specificity, is capable of specifically catalyzing L-glutamate and can be applied to the content detection of L-glutamate and the fields of food industries and clinical biochemistry detection.

The present invention relates to an arginine deiminase mutant with partial lysine-deficient and preparation and application thereof. The arginine deiminase mutant of the present invention has enzymatic activity of degrading arginine into citruline; compared with the arginine deiminase with the amino acid sequence of SEQ ID NO: 1, the amino acid sequence comprises one or more of K9N, T, K59Q, K66R, A, K93E, A, Q, K111R, A, K119Q, L, M, K121Q, I, K122E, L, K126E, S, R, K178I, E, D, K196I, R, K209G, T, D, K243E, V, R, K249D, Q, K263N, Q, K279Y, T, K293R, H, E, K325V, I, K380T, R, E, and K406E, D, S substitutions. Compared with PEG modified natural derived arginine deiminase, the PEG modified arginine deiminase mutant of the present invention retain better bioactivity; and because the quantity of lysine in arginine deiminase is reduced, the PEG modified products are more uniform and can be applied to clinical treatment of hepatoma, melanoma and the like.

The invention discloses a parathyroid hormone (PTH) derivative which has an amino acid sequence shown in SEQ ID NO: 1. With glutamic acid as a spacer, epsilon-amino of lysine at the 26-th position is connected with a lipophilic group W which has 12-40 carbon atoms and selectively contains a group capable of carrying negative charges so as to finally obtain the PTH derivative. Compared with PTH, the derivative has longer in vivo half-life period; therefore, the PTH administration frequency can be reduced, and compliance and treatment effect of medicines can be improved.

Isolated peptides of 13-30 amino acids comprising 5-9 consecutive repeats of the amino acid pair Alanine-Leucine or Alanine-Valine are provided. The peptides further comprise a stretch of 1-3 Lysine residues present at least at one of the peptide's termini, wherein the only Lysine residue in the isolated peptide is present at the stretch of 1-3 Lysine residues. Pharmaceutical compositions comprising same, methods of treating inflammatory conditions and allergic reactions, as well as methods of neutralizing the activity of lypopolysaccharides are also provided.

Nucleic acid sequences, vectors, recombinant host cells, transgenic plants, and methods for their preparation are disclosed. The nucleic acid sequences encode threonine deaminase proteins that catalyze the conversion of threonine to α-ketobutyrate. One or both of the amino acids at positions 447 and 481 of the encoded proteins can be selected from groups of particular amino acids. For example, the amino acid at position 447 can be alanine, isoleucine, valine, phenylalanine, tryptophan, or methionine. The amino acid at position 481 can be alanine, isoleucine, proline, phenylalanine, tryptophan, or methionine.

Provided herein are compositions comprising amino acids and uses of such compositions to aid in recovery from exercise, illness or injury, in performance during exercise, in survival in extreme climatic conditions, and to reduce fatigue. The present disclosure relates to amino acid supplements, which may serve to supplement amino acids lost in sweat.

A human cholesterol ester synthetase ACTA-1b, its coding sequence, the configurator containing said sequence, its carrier and its application in preparing the medicines for treating hypercholesterinema, atherosclerosis and senile dementia.

The invention provides a chemiluminescence kit for detecting EB virus Rta / IgG antibody and a use thereof and belongs to the fields of biotechnology, medical immunology and external serology diagnosis. The chemiluminescence kit comprises magnetic particles coated with an anti-His label monoclonal antibody, a Rta protein with a His label, a specific synthetic polypeptide with a His label and an acridinium ester-labeled anti-human IgG antibody. The specific synthetic polypeptide has an amino acid sequence shown in the formula of SEQ ID NO: 1. The invention also provides a method for detecting an EB virus Rta / IgG antibody by the chemiluminescence kit. The chemiluminescence kit and the detection method can realize fast, accurate, efficient, sensitive and specific detection of an EB virus Rta protein antibody in a sample to be detected, realize multiple sample treatment, shorten detection time and improve detection efficiency.

Methods, and compositions derived thereof, for preparing a myceliated amino-acid-supplemented high-protein food product having desired digestibility and amino acid content. An aqueous medium comprising a high-protein material is inoculated with a fungal culture to produce a myceliated amino acid-supplemented high-protein food product. The plant protein can include pea, rice and / or chickpea protein. The fungi can include Lentinula spp., Agaricus spp., Pleurotus spp., Boletus spp., or Laetiporus spp. Preferably, the myceliated amino acid-supplemented high-protein food product has reduced bitterness and / or reduced volatile amino-acid-derived aroma compared to high-protein amino acid-supplemented material that is not myceliated. Also disclosed are myceliated amino-acid-supplemented high-protein food products and compositions, such as dairy alternative products, beverages and beverage bases, extruded and extruded / puffed products, meat analogs and extenders, baked goods and baking mixes, texturized plant-based protein products, granola products, bar products, smoothies and juices, and soups and soup bases.

The invention relates to antibodies for resisting human streptococcus pneumoniae fam2 family PspA protein and an immunochromatographic kit applying the antibodies to detection on human streptococcus pneumoniae. The antibodies for resisting the human streptococcus pneumoniae fam2 family PspA protein are used for recognizing two linear antigenic epitopes composed of 34-47 amino acids and 274-287 amino acids of the human streptococcus pneumoniae fam2 family PspA protein respectively, and the sequence number of the human streptococcus pneumoniae fam2 family PspA protein in GenBank is WP_054380072.1; the sequences of the 34-47 amino acids and the 274-287 amino acids of the human streptococcus pneumoniae fam2 family PspA protein are SPQVVEKSSLEKKY and KLLDSLDPEGKTQD respectively. The two rabbit antibodies for resisting the human streptococcus pneumoniae fam2 family PspA protein have the advantages of being good in specificity, high in purity and titer and low in preparation cost.

The invention relates to a plant-based glutamic acid rich protein composition and method of making the same. The composition provides a spectrum of amino acids, including an abundance of glutamic acid. The composition is free of the antibiotics and growth hormones associated with animal-sourced proteins and does not require amino acid supplementation to achieve high levels of glutamic acid. In some aspects, the composition is obtained from coffee beans, including defatted green coffee beans.

The invention describes a retro-inverso (RI) gonadotropin-releasing hormone (GnRH) peptide which is capable of eliciting an immune response directed against GnRH, the peptide having the amino acid sequence GPRLGYSWHX, wherein the amino acids are D-amino acids and X is any amino acid. More particularly, X is E, Q, P or G, and even more particularly, X is E or Q. Thus, a preferred amino acid sequence for the peptide is GPRLGYSWHE. The peptide may optionally include one or more additional D-amino acids at its N- or C-terminus, for example a cysteine residue or a series of linker amino acids, such as a plurality of glycine amino acid residues. Thus, a second preferred amino acid sequence for the peptide is GPRLGYSWHEC, which includes a cysteine residue at the C-terminus for conjugation purposes. The invention also describes a vaccine composition for use in controlling fertility, heat, contraception and / or treating sex hormone-related diseases, and a method for controlling and or treating fertility and sex hormone-related diseases.